



The Evolving Treatment Journey for Patients With Unresectable Stage III NSCLC in the Era of Immune Therapy

Clinical Brief 1 – Standard-of-Care Management of Unresectable Stage III NSCLC

References

Tweet 2 Reference:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Non-small cell lung cancer (v5.2023). Updated November 8, 2023. Accessed December 11, 2023. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Additional References:

Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *N Engl J Med*. 2017;377(20):1919-1929. doi:10.1056/NEJMoa1709937

Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. *J Clin Oncol*. 2022;40:1301-1311. doi:10.1200/JCO.21.01308

Glossary

AUC, area under the curve
CT, chemotherapy
Durva, durvalumab
ECOG, Eastern Cooperative Oncology Group
IV, intravenous
NCCN, National Comprehensive Cancer Network
NSCLC, non-small cell lung cancer
PR, partial response
PS, performance status
Q2W, every 2 weeks
RT, radiation therapy
SOC, standard of care
w/, with
y, year
yo, year old